Cell-Based Therapy for the Treatment of Glioblastoma: An Update from Preclinical to Clinical Studies
2022
Noha Attia | Mohamed Mashal | Sudhakar Pemminati | Adekunle Omole | Carolyn Edmondson | Will Jones | Priyanka Priyadarshini | Temoria Mughal | Pauline Aziz | Blesing Zenick | Ambar Perez | Morgan Lacken
Glioblastoma (GB), an aggressive primary tumor of the central nervous system, represents about 60% of all adult primary brain tumors. It is notorious for its extremely low (~5%) 5-year survival rate which signals the unsatisfactory results of the standard protocol for GB therapy. This issue has become, over time, the impetus for the discipline of bringing novel therapeutics to the surface and challenging them so they can be improved. The cell-based approach in treating GB found its way to clinical trials thanks to a marvelous number of preclinical studies that probed various types of cells aiming to combat GB and increase the survival rate. In this review, we aimed to summarize and discuss the up-to-date preclinical studies that utilized stem cells or immune cells to treat GB. Likewise, we tried to summarize the most recent clinical trials using both cell categories to treat or prevent recurrence of GB in patients. As with any other therapeutics, cell-based therapy in GB is still hampered by many drawbacks. Therefore, we highlighted several novel techniques, such as the use of biomaterials, scaffolds, nanoparticles, or cells in the 3D context that may depict a promising future when combined with the cell-based approach.
显示更多 [+] 显示较少 [-]